Show simple item record

dc.contributor.authorBurnett, A K
dc.contributor.authorRussell, N H
dc.contributor.authorHills, R K
dc.contributor.authorKell, J
dc.contributor.authorNielsen, O J
dc.contributor.authorDennis, M
dc.contributor.authorCahalin, P
dc.contributor.authorPocock, C
dc.contributor.authorAli, S
dc.contributor.authorBurns, S
dc.contributor.authorFreeman, S
dc.contributor.authorMilligan, D
dc.contributor.authorClark, R E
dc.date.accessioned2016-10-21T10:05:15Z
dc.date.available2016-10-21T10:05:15Z
dc.date.issued2016-09-30
dc.identifier.citationA comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. 2016 Leukemiaen
dc.identifier.issn1476-5551
dc.identifier.pmid27624670
dc.identifier.doi10.1038/leu.2016.225
dc.identifier.urihttp://hdl.handle.net/10541/619956
dc.description.abstractThe study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and normal serum creatinine were randomised to two courses of induction chemotherapy with either daunorubicin/ara-C (DA) or daunorubicin/clofarabine (DClo). Patients were also included in additional randomisations; ± one dose of gemtuzumab ozogamicin in course 1; 2v3 courses and ± azacitidine maintenance. The primary end point was overall survival. The overall response rate was 69% (complete remission (CR) 60%; CRi 9%), with no difference between DA (71%) and DClo (66%). There was no difference in 30-/60-day mortality or toxicity: significantly more supportive care was required in the DA arm even though platelet and neutrophil recovery was significantly slower with DClo. There were no differences in cumulative incidence of relapse (74% vs 68%; hazard ratio (HR) 0.93 (0.77-1.14), P=0.5); survival from relapse (7% vs 9%; HR 0.96 (0.77-1.19), P=0.7); relapse-free (31% vs 32%; HR 1.02 (0.83-1.24), P=0.9) or overall survival (23% vs 22%; HR 1.08 (0.93-1.26), P=0.3). Clofarabine 20 mg/m(2) given for 5 days with daunorubicin is not superior to ara-C+daunorubicin as induction for older patients with AML/high-risk MDS.Leukemia advance online publication, 30 September 2016; doi:10.1038/leu.2016.225.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Leukemiaen
dc.titleA comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.en
dc.typeArticleen
dc.contributor.departmentDepartment of Haematology, Cardiff University School of Medicine, Cardiff, UKen
dc.identifier.journalLeukemiaen
refterms.dateFOA2018-12-17T14:40:27Z
html.description.abstractThe study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and normal serum creatinine were randomised to two courses of induction chemotherapy with either daunorubicin/ara-C (DA) or daunorubicin/clofarabine (DClo). Patients were also included in additional randomisations; ± one dose of gemtuzumab ozogamicin in course 1; 2v3 courses and ± azacitidine maintenance. The primary end point was overall survival. The overall response rate was 69% (complete remission (CR) 60%; CRi 9%), with no difference between DA (71%) and DClo (66%). There was no difference in 30-/60-day mortality or toxicity: significantly more supportive care was required in the DA arm even though platelet and neutrophil recovery was significantly slower with DClo. There were no differences in cumulative incidence of relapse (74% vs 68%; hazard ratio (HR) 0.93 (0.77-1.14), P=0.5); survival from relapse (7% vs 9%; HR 0.96 (0.77-1.19), P=0.7); relapse-free (31% vs 32%; HR 1.02 (0.83-1.24), P=0.9) or overall survival (23% vs 22%; HR 1.08 (0.93-1.26), P=0.3). Clofarabine 20 mg/m(2) given for 5 days with daunorubicin is not superior to ara-C+daunorubicin as induction for older patients with AML/high-risk MDS.Leukemia advance online publication, 30 September 2016; doi:10.1038/leu.2016.225.


Files in this item

Thumbnail
Name:
leu2016225a.pdf
Size:
1020.Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record